MTOR and cancer: These results are in agreement with those described previously, which reported that CAFs could promote resistance to trastuzumab in HER2-positive BCCLs by activating pathways such us PI3K/AKT/mTOR and JAK/STAT3, as well as by expanding cancer stem cells (CSCs) [21].